SPARC's Board approved the financial results for the quarter, with a consolidated loss of ₹20.78 Cr.

The board also approved reclassifying certain promoter group individuals.

During the quarter, 3.85 Cr warrants were allotted preferentially at ₹155.80 each, and a licensing agreement was terminated, refunding $2M.

No comments yet. Be the first.

More from Sun Pharma Advanced Research Company Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.